FDA identifies 20 drugs that need approved risk eval, strategy

Share this article:
FDA identified 20 Rx drugs and biologics that must have an approved risk evaluation and mitigation strategy, including GlaxoSmith-Kline's Lotronex, Novartis' Clozaril, Cephalon's Actiq, Hoffmann-LaRoche's Accutane, Celgene's Revlimid and Thalomid, Danco's Mifeprex and Biogen Idec's Tysabri.
Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.